Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + doxorubicin + fluorouracil + leucovorin + sargramostim
- Development stage
- Preclinical
- Lead developer
- Takeda
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination chemotherapy regimen consisting of cyclophosphamide (an alkylating agent), doxorubicin (an anthracycline), fluorouracil (an antimetabolite), leucovorin (a reduced form of folate), and sargramostim (granulocyte-macrophage colony-stimulating factor). This combination is likely used in the treatment of advanced cancers, particularly breast cancer, with sargramostim added to support bone marrow recovery from the cytotoxic effects of the chemotherapy agents.
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)TS (Thymidylate synthase)DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cyclophosphamide + doxorubicin + fluorouracil + leucovorin + sargramostim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + doxorubicin + fluorouracil + leucovorin + sargramostim.